Drug intelligence / Profile preview

RENB-HV-21 (Renovaro Inc.)

Development stage: Preclinical
Lead developer: Renovaro
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

RENB-HV-21 is an innovative experimental treatment for HIV being developed by Renovaro BioSciences. The therapy utilizes **allogeneic Natural Killer (NK) cells and Gamma Delta T-cells (GDT)** as its mechanism of action. This represents a novel approach to HIV treatment through **cell-based immunotherapy**, leveraging the immune system's natural ability to target infected cells. The treatment is currently in the exploratory development phase as part of Renovaro's broader pipeline of HIV therapeutics.

Beyond the preview

Go deeper on RENB-HV-21 (Renovaro Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RENB-HV-21 (Renovaro Inc.).

Explore the full profile